Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

Relief over a US-EU trade deal today benefited the FTSE 100 index in a session when leading European benchmarks rose by as ...

Asian equities were mostly higher overnight as Vietnam and Indonesia outperformed while Japan and India underperformed. Hong ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

(Alliance News) - GSK announced a partnership with China's Hengrui, Cranswick said it expects results in line with market expectations, while STV warned of an annual outcome below consensus. Here is ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

GSK is scheduled to report results for the first quarter on Wednesday. Here is what to know. SALES FORECAST: The British pharmaceutical giant is expected to report sales for the period of 7.42 ...

We aim to explore its current performance. Present Market Standing of GSK With a volume of 19,701,072, the price of GSK is up 5.97% at $40.29.

GSK GSK 0.99 % increase; green up pointing triangle plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.